header logo image


Page 328«..1020..327328329330..340350..»

Future Meat is cutting costs on mass production with an unlikely cellular approach – The Spoon

November 30th, 2020 7:57 am

Founded in 2018, Future Meat stayed under the radar until last fall when their Series A funding round raised $14 millionincluding a sizable investment from Tyson Ventures. Now, just two years in, theIsraeli start-up is expecting a major scale up in early 2021 and is optimistic about being among the first to gain FDA approval thanks to an uncommon cellular approach.

Commercial scale has been Future Meats priority from the start. We know we can [culture meat]. The question is how much will it cost, said Yaakov Nahmias, Future Meat Chief Scientific Officer told me in an interview earlier this month. Do you really want to make a $25,000 steak?

Key to its plan to ramp up biomass and cut costs, is a unique choice of starter cells. While most cultured meat start-ups rely on some form of stem or muscle cell, the basic building block of Future Meats products is the cell-type that makes up your connective tissue: fibroblasts.

These are the cells that every time you get cut, they close that cut very fast, according to Nahmias, who developed the fibroblast technology in his university lab.

Stem cells are a popular candidate for cell culture because they can become any type of cell, but growing and maintaining them is very expensive, Nahimas said. Theyre what we call phenotypically unstable. Meaning, stem cells dont stay stem cells for long. In nature, theyre meant to be stem cells for a day or less before transforming into another cell type. To harness their potential or stabilize stem cells, many start-ups rely on gene editing, a method that Future Meat is avoiding.

Fibroblasts, on the other hand, are phenotypically stable making them less volatile and easier to grow in mass quantities. And Future Meat has an extensive patent portfolio protecting the way they growand direct these fibroblasts. They can accelerate a natural process called spontaneous immortalization where the cells DNA rearranges so that it can divide forever. And by adding some food grade molecules to the cellular medium they can pressure the fibroblast to become fat cells or muscle cells, Nahmias said.

Another key advantage of these connective tissue cells is that Future Meat can grow them in suspension, they dont require surfaces to cling to. Many other mammalian cells, like muscle cells (myocytes), need something to hold on to, a sort of scaffolding, when cultured. Culturing in suspension means no need for scaffolding and it significantly increases the biomass that can be cultivated in a single bioreactor.According to Kate Krueger, alternative protein consultant at Helikon Consulting, Suspension cell culture has a lot of promise in reducing cost of manufacture.

Today, Future Meat bioreactor systems can reach yields of 33 percent, converting a third of their volume to mass every two weeks. Its possible to grow the mass of 100 chickens every two weeks in a bioreactor the size of a standard refrigerator, Nahmias said. Theyre also working on a hybrid product, a combination of plant protein and bioreactor-grown fat cells that they can produce at two tons per week. By the second quarter of next year they expect peak capacity to increase to half a ton every two weeks and for that to triple again by the end of 2021.

For now Future Meat is all about getting to scale, market and a reasonable price point to validate their process and prove their tech. But the end-game for Future Meat is about developing a platformthink of it as the AWS of cultured meat. And the target customer isnt just a new meat industry, its the old one.

The idea is to integrate their technology into the existing supply chain. Even individual farmers looking to diversify could include a bioreactor as part of their operations, Nahmias said. But he expects involvement from meat and ingredient giants like Tyson and Cargill will be what finally catapults cultured meat into the mainstream. Future Meats game plan is to have the approved and affordable tech ready and waiting. Because once it happens, he said, its going to move quickly.

Related

Read more from the original source:
Future Meat is cutting costs on mass production with an unlikely cellular approach - The Spoon

Read More...

Mutations of the coronavirus do not appear to make the virus more infectious, study says | TheHill – The Hill

November 30th, 2020 7:54 am

None of the mutations observed in the coronavirus that causes COVID-19 appear to increase the viruss transmissibility, a new study says.

The study led by researchers from University College London published Wednesday in Nature Communications analyzed a global dataset of virus genomes from more than 46,000 people with COVID-19 from 99 countries.

Our country is in a historic fight against the Coronavirus. Add Changing America to your Facebook or Twitter feed to stay on top of the news.

Researchers so far have identified more than 12,700 mutations in the SARS-CoV-2 virus.

Coronaviruses like SARS-CoV-2 mutate all the time and most are neutral. But some can be advantageous or detrimental to the virus, potentially with troublesome consequences, such as making the virus more contagious and a vaccine less effective.

But so far, researchers say they have yet to find any evidence common mutations are increasing the viruss transmissibility.

We realised early on in the pandemic that we needed new approaches to analyze enormous amounts of data in close to real time to flag new mutations in the virus that could affect its transmission or symptom severity, Lucy van Dorp, a professor at University College Londons Genetics Institute and a lead researcher of the study, said in a statement.

Fortunately, we found that none of these mutations are making COVID-19 spread more rapidly, but we need to remain vigilant and continue monitoring new mutations, particularly as vaccines get rolled out, she said.

Researchers found most of the viruss mutations occurred as a result of the human immune system response, rather than the result of the virus adapting to its human host.

Over the course of the pandemic, one mutation in the virus spike protein called D614Gwas reported as being a mutation that could make the virus more contagious than earlier strains that emerged out of Wuhan, China.

The study published Wednesday found the mutation is in fact not associated with a greater increase in transmission.

Francois Balloux, a UCL professor who worked on the research, said the virus posed no threat to COVID-19 vaccine efficacy at this time but warned the introduction of vaccines could exert new selective pressures on the virus to mutate to escape recognition by the humane immune system.

The news on the vaccine front looks great. The virus may well acquire vaccine-escape mutations in the future, but were confident well be able to flag them up promptly, which would allow updating the vaccines in time if required, Balloux said.

WHAT YOU NEED TO KNOW ABOUT CORONAVIRUS RIGHT NOW

ONE THIRD OF PARENTS SAY THANKSGIVING WITH FAMILY IS WORTH THE RISK OF COVID-19

FAUCI CONFIRMS COVID-19 VACCINE COULD BE READY BY LATE DECEMBER, EARLY 2021

HOW TO COMPARE THE COVID-19 VACCINES FROM ASTRAZENECA, MODERNA AND PFIZER

SOUTH DAKOTA GOVERNOR REFUSES TO MANDATE MASKS DESPITE RECORD-BREAKING CORONAVIRUS SPIKE

PROJECTED US CORONAVIRUS DEATHS MORE THAN 400,000 BY MARCH

Read the original:
Mutations of the coronavirus do not appear to make the virus more infectious, study says | TheHill - The Hill

Read More...

Spaceflight does some weird things to astronauts bodies – MIT Technology Review

November 30th, 2020 7:54 am

The Twins Study gave us a first sketch of the human bodys molecular responses to spaceflight, but these outlines needed to be filled in, says Christopher Mason, an associate professor of physiology and biophysics at Weill Cornell Medicine. The changes we saw needed more context and replication. We needed additional studies to map out the frequency of the changes we observed in other astronauts, and other organisms, that go into space, and also to see if the degree of change was similar for shorter missions.

That brings us to a new package of research that builds on the Twins Study, reanalyzing some of the original data with new techniques and providing comparisons with other astronauts. In a set of 19 studies published today in a slew of different journals (along with 10 preprints still under peer review), researchers like Mason (a senior author on 14 of the papers) studied the physiological, biochemical, and genetic changes that occurred in 56 astronauts (including Kelly) who have spent time in spacethe largest study of its kind ever conducted.

The new papers, which incorporate results from cell-profiling and gene-sequencing techniques that have become easier to run only recently, reveal that there are some features of spaceflight that consistently appear in humans, mice, and other animals when they go to space, says Mason. There appears to be a core mammalian set of adaptations and responses to the rigors of spaceflight.

The researchers highlightsix biological changesthat occur in all astronauts during spaceflight: oxidative stress (an excessive accumulation of free radicals in the bodys cells), DNA damage, dysfunction of the mitochondria, changes in gene regulation, alterations in the length of telomeres (the ends of chromosomes, which shorten with age), and changes in the gut microbiome.

Of these six changes, the biggest and most surprising one for scientists wasmitochondrial dysfunction. Mitochondria play a critical role in producing the chemical energy necessary to keep cellsand by extension, tissue and organsfunctional. Researchers found irregular mitochondrial performance in dozens of astronauts and were able to broadly characterize these changes thanks to new genomics and proteomics techniques. Afshin Beheshti, a bioinformatician at NASA and senior author of one study, says mitochondrial suppression helps explain how many of the problems astronauts experienced (like immune system deficiencies, disrupted circadian rhythm, and organ complications) are actually holistically related to each other, since they all rely on the same metabolic pathways.

When youre in space, its not just one are or organ thats affected, its the whole body thats affected, says Beheshti. "We started connecting the dots."

Other research homed in on problems observed at the genetic level. The Twins Study showed that Kellys telomeres got longer in space before shrinking back to normal or even shorter lengths soon after he returned to Earth. Telomeres are supposed to shorten with age, so lengthening makes little sense, and the Twins Study didnt provide enough data to prompt any real conclusions as to why it happened and what the effects were.

Susan Bailey, a Colorado State University expert on telomere research and a senior author for several of the papers, says the new research found that 10 other astronautsexperienced the same telomere lengthening Kelly did irrespective of mission durationas well as the same telomere shrinking once they came back to Earth.

Notably, one of the papers in the new package found that longer telomeres were also associated with climbers of Mount Everest. For Bailey and her colleagues, this suggests that telomere lengthening isaffected by oxidative stresssomething that climbers and astronauts both experience, and that disrupts proper telomere maintenance.

NASA

They are still trying to pinpoint how these pathways work and exactly what the consequences could be (its probably not a secret to longevity), but we now have a foundation to build onwe know what to look for and be aware of in future astronauts on long-duration [and deep space] exploration missions, she says.

Though some of the changes are unexpected, many are no cause for concern. What is amazing to me is how well we adapt to space, says Jeffrey Sutton, director of the Baylor College of Medicines Center for Space Medicine, who was not involved with the new research.Blood cell mutations decreased in Kelly while he was in space(a total surprise for Mason). Astronauts also exhibiteddecreased levels of biomarkers associated with agingandincreased levels of microRNAsthat regulate the vascular systems response to radiation damage and microgravity. One of the strangest findings was that astronauts gut microbiomes managed to bring space microbes found on the ISS back to Earth.

The studies individually and collectively are truly impressive, says Sutton. We have entered a new era of space biomedical research, where the approaches and tools of precision and translational medicine are being applied to advance our understanding of human adaptation to space.

Ultimately, however, the data highlights just how much havoc and stress even the healthiest bodies face during space missionswhich should have an impact on planning for longer missions. I dont think were close to sending untrained people into space for really long periods of time, says Scott Kelly.

Physiologically, he thinks its probably safe to send people to Mars and back. In the distant future, however, instead of going to Mars, were going to be going to the moons of Jupiter or Saturn, he says. Youre going to be in space for years. And at that point, well have to take a closer look at artificial gravity as a mitigation. I wouldnt want to be arriving on the surface of another planetary body and not be able to function. A year or so is workable. Several years probably isnt.

NASA

Were still far away from having to evaluate those kinds of risks. Mason and his colleagues suggest that there should be pharmacological strategies for reducing the impact of gravity on the bodies of returning astronauts.

Sutton believesprecision medicinecould play a huge role in tailoring those drugs to protect astronauts against the effects of microgravity and radiation. And the shared biological responses between astronauts and Mount Everest climbers suggest that some interventions used to protect extreme sports athletes from oxidative stress could be applied to astronauts too.

What we need is more dataand more populations to use for comparison. Mason, Bailey, and their colleagues are starting to collect cell and gene profiles of more astronauts, especially those going on future year-long missions. They also want to study people whove experienced other conditions similar in some way to spaceflight, such as radiotherapy patients, pilots, and flight attendants.

The more we know about the health effects of long-duration spaceflight, the better able we will be to help maintain the health and performance of astronauts during and after spaceflight, says Bailey. Such knowledge benefits those of us on Earth as wellwe are all concerned about getting older, and being in poor health.

This post has been updated with comments from Afshin Beheshti.

Read this article:
Spaceflight does some weird things to astronauts bodies - MIT Technology Review

Read More...

Precision Medicine Software Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top…

November 30th, 2020 7:54 am

Precision Medicine Software Marketis anticipated to discover Robust Growth by 2026. This report focuses on the leading key players with global perspective with a professional and in-depth study on the current state of Precision Medicine SoftwareIndustry. Precision Medicine Softwaremarket research report provides important market strategies and Latest trends with discussion of market consumption, major drivers, restraints and market share forecasted to 2026.

The Precision Medicine Software Market Report further describes detailed information about tactics and strategies used by leading key companies in the Precision Medicine Softwareindustry. It also gives an extensive study about different market segments and regions.

The Precision Medicine Softwaremarket report provides answers to the following key questions:

To get more information, Ask for Sample PDF:https://inforgrowth.com/sample-request/6461601/precision-medicine-software-market

The Precision Medicine SoftwareMarket report provides basic information about Precision Medicine Softwareindustry, definition, classification, application, industry chain structure, industry overview; international market analysis. This report studies sales (consumption) of Precision Medicine Softwaremarket, focuses on the top players, with sales, price, revenue and market share with volume and value for each region.

Top Key Players in Precision Medicine Softwaremarket: Syapse, , Allscripts, , Qiagen, , Roper Technologies, , Fabric Genomics, , Foundation Medicine, , Sophia Genetics, , PierianDx, , Human Longevity, , Translational Software, , Gene42, Inc, , Lifeomic Health

Precision Medicine SoftwareMarket on the basis of Product Type:Cloud-based, , On-premise

Precision Medicine SoftwareMarket on the basis of Applications:Healthcare Providers, , Pharmaceutical and Biotechnology Companies, , Research Centers and Government Institutes, , Others,

Get up to 30% instant discount Under Our Thanksgiving Discount OFFER;https://inforgrowth.com/discount/6461601/precision-medicine-software-market

Impact of COVID-19:

Precision Medicine SoftwareMarket report analyses the impact of Coronavirus (COVID-19) on the Precision Medicine Softwareindustry.Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Precision Medicine Softwaremarket in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get the Sample ToC and understand the COVID19 impact and be smart in redefining business strategies.https://inforgrowth.com/CovidImpact-Request/6461601/precision-medicine-software-market

Key Questions Answered in this Report:

What is the market size of the Precision Medicine Softwareindustry?This report covers the historical market size of the industry (2013-2019), and forecasts for 2020 and the next 5 years. Market size includes the total revenues of companies.

What is the outlook for the Precision Medicine Softwareindustry?This report has over a dozen market forecasts (2020 and the next 5 years) on the industry, including total sales, a number of companies, attractive investment opportunities, operating expenses, and others.

What industry analysis/data exists for the Precision Medicine Softwareindustry?This report covers key segments and sub-segments, key drivers, restraints, opportunities, and challenges in the market and how they are expected to impact the Precision Medicine Softwareindustry. Take a look at the table of contents below to see the scope of analysis and data on the industry.

How many companies are in the Precision Medicine Softwareindustry?This report analyzes the historical and forecasted number of companies, locations in the industry, and breaks them down by company size over time. Report also provides company rank against its competitors with respect to revenue, profit comparison, operational efficiency, cost competitiveness and market capitalization.

What are the financial metrics for the industry?This report covers many financial metrics for the industry including profitability, Market value- chain and key trends impacting every node with reference to companys growth, revenue, return on sales, etc.

What are the most important benchmarks for the Precision Medicine Softwareindustry?

Is there any query? Ask to our Industry Expert: https://inforgrowth.com/enquiry/6461601/precision-medicine-software-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898

See the rest here:
Precision Medicine Software Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top...

Read More...

Neuropathy Pain Treatment Market Size, Share, Statistics, Trends, Demand and Revenue, Forecast To 2027 – The Haitian-Caribbean News Network

November 30th, 2020 7:53 am

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Neuropathy Pain Treatment Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Neuropathy Pain Treatment Market Overview

The Neuropathy Pain Treatment Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Neuropathy Pain Treatment market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Neuropathy Pain Treatment Market: Competitive Landscape

The Neuropathy Pain Treatment Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Neuropathy Pain Treatment Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Neuropathy Pain Treatment Market Segment by Type:

Neuropathy Pain Treatment Market Segment by Application:

Neuropathy Pain Treatment Market Regional overview:

In the report, experts analyze and forecast the Neuropathy Pain Treatment market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Neuropathy Pain Treatment Market Report:

Outlook analysis of the Neuropathy Pain Treatment market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Neuropathy Pain Treatment market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Read the original post:
Neuropathy Pain Treatment Market Size, Share, Statistics, Trends, Demand and Revenue, Forecast To 2027 - The Haitian-Caribbean News Network

Read More...

Ischemic Optic Neuropathy Treatment Market set to witness surge in demand over the forecast period 2020-2030 – Murphy’s Hockey Law

November 30th, 2020 7:53 am

Global Ischemic Optic Neuropathy Treatment Market: Overview

Technological progress made in the treatment of ischemic optic neuropathy coupled with the availability of alternative drugs is expected to boost the growth of the global ischemic optic neuropathy treatment market over the period of analysis, from 2020 to 2030. Ischemic optic neuropathies(IONs) are one of the major reasons for seriously impaired vision or blindness usually amongst the elderly and middle-aged people. However, the disease can affect anyone and no human age is immune to it. Increased prevalence of the disease is anticipated to propel expansion of the global ischemic optic neuropathy treatment market in the years to come.

Ischemic optic neuropathies (IONs) come in two types, namely posterior ischemic optic neuropathy (PION) and anterior ischemic optic neuropathy (AION). Inflammation of the arteries that supply blood to the optic nerve causes anterior ischemic optic neuropathy and reasons other than inflammation cause non-anterior ischemic optic neuropathy. However, anterior ischemic optic neuropathy is more commonly found in people than posterior ischemic optic neuropathy. Immediate treatment is needed in case of anterior ischemic optic neuropathy to prevent loss of vision in the affected eye as it also causes damage in the other eye in a span of just 5 to 10 days.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78358

Hypercholesterolemia, diabetes, and hypertension are some of the causes of the disease. In addition, other medical conditions such as failure of autoregulation, severe anemia, vasospasm, nocturnal hypotension, sleep apnea, and hypoperfusion are likely to cause ischemic optic neuropathies.

Disease type, treatment type, end user, and region are the four important parameters based on which the global ischemic optic neuropathy treatment market has been classified. The thorough evaluation of the market comes with the objective of providing stakeholders with a detailed and clear analysis of the global ischemic optic neuropathy treatment market.

Request for Analysis of COVID19 Impact on Ischemic Optic Neuropathy Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78358

Global Ischemic Optic Neuropathy Treatment Market: Notable Developments

One of the significant developments that give a quick view of the dynamics pertaining to the global ischemic optic neuropathy treatment market is mentioned as below:

Some of the prominent organizations in the global Ischemic optic neuropathy treatment market comprise the below-mentioned:

Pre book Ischemic Optic Neuropathy Treatment Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=78358&ltype=S

Global Ischemic Optic Neuropathy Treatment Market: Key Trends

The global ischemic optic neuropathy treatment market is characterized by the presence of the following restraints, drivers, and opportunities.

Increased Demand from Various End Use Sectors to Fuel Market Growth

The development of the global ischemic optic neuropathy treatment market is anticipated to register high growth rate over the tenure of assessment. The increased use of intravitreal implants for treating ophthalmology diseases is expected to open new avenues of growth for the global ischemic optic neuropathy treatment market over the forecast period, from 2020 to 2030. Many of the leading drug manufacturing and pharmaceutical companies from the developed countries are making high investment in the research and development activities so to develop better and advanced solutions and reduce the burden of vision and eye-related diseases. Increased spending in infrastructure and new, advanced technologies in ophthalmology therapeutics are likely to account for a larger share of the market in the years to come.

For patients suffering from ischemic optic neuropathy, corticosteroid is considered as the first choice of therapy, particularly in countries like Russia, France, Germany, and the US. However, several patients have developed resistance to anti-VEGF, which is likely to boost growth of the global ischemic optic neuropathy treatment market over the period of analysis, from 2020 to 2030.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read more here:
Ischemic Optic Neuropathy Treatment Market set to witness surge in demand over the forecast period 2020-2030 - Murphy's Hockey Law

Read More...

Man jailed for distributing methamphetamine to be released after proof of physical ailments – Pacific Daily News

November 30th, 2020 7:53 am

Staff Reports Published 6:41 p.m. ChT Nov. 30, 2020

Mark Torre Jr. and his attorney Jay Arriola react after a jury found Torre not guilty of all charges on Nov. 23, 2020. Pacific Daily News

A man sentenced to prison for distributing methamphetamine will be released after the court found substantial evidence of physical ailments, including contracting the coronavirus twice.

On July 25, 2016, the court sentenced Franklin John Salas to nine years imprisonment.Salas has served 60% of his prison sentence, and at sentencing was assigned the lowest criminal history category because his crime was nonviolent.

According to the District Court of Guam, Salas suffers from Type II diabetes, diabetic neuropathy, eye cataracts, hypertension, pressure ulcers on his buttocks and foot, chronic kidney disease, and obesity.

In 2016, he suffered a hip fracture and had surgery. In 2017, he fractured his right knee, which according to court documents, doctors at the prison have been unable to treat.

"Walking on his own is extremely painful, and so (he) has been confined to a wheelchair for the last four years," court documents read. Since the start of his incarceration, Salas gained 50 pounds.

More: GPD investigating skull found on shoreline in Hagta

During the coronavirus outbreak, Salas was infected with the coronavirus twice. He has since suffered chills, body aches, loss of appetite, loss of taste, and fatigue, according to court documents.

"He has difficulty in wheeling himself around because of this fatigue, and thus must always have a fellow prisoner assigned to help push his wheelchair," court documents state. Salas also lives in the same room as dozens of other inmates, and they share three bathrooms and one urinal.

More: Don't click that link: Free chicken announcement on WhatsApp is a hoax, KFC Guam says

The court has reduced his sentence to the time he served, and will release him, subject to the surrender of his passport and regular monitoring.

Salas still faces three years of supervised release, during which he will have to comply with conditions already imposed on him.

Read or Share this story: https://www.guampdn.com/story/news/local/2020/11/30/man-jailed-distributing-methamphetamine-released-after-proof-physical-ailments/6461376002/

Continue reading here:
Man jailed for distributing methamphetamine to be released after proof of physical ailments - Pacific Daily News

Read More...

MediciNova’s Ibudilast Reduces Retinal Thinning in MS Trial Subjects – BioSpace

November 30th, 2020 7:53 am

MediciNovaannounced today that it received positive Optical Coherence Tomography (OCT) results from its SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis (MS) subjects. The results were published in the Multiple Sclerosis Journal.

A total of 28 sites participated in the trial, with 22 sites using Zeiss Cirrus OCT and six sites utilizing Heidelberg Spectralis OCT. In all, 183 subjects were imaged with Cirrus, while 61 were imaged with Spectralis. All of the OCT measures showed less loss of retinal tissue in subjects who received MN-166, compared to a placebo.

Change in peripapillary retinal nerve fiber layer thickness was +0.0424 uM/year for MN166 (ibudilast) versus 0.2630 uM/year for the placebo. Macular volume change was 0.00503 mm3/year for MN-166 compared to 0.03659 mm3/year for placebo in the Spectralis arm. In the Cirrus cohort, macular volume change was 0.00040 mm3/year for MN-166 (ibudilast) compared to 0.02083 mm3/year for the placebo.

We are very pleased that the positive OCT data has been published, said Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc. This data demonstrates that MN-166 can reduce retinal thinning in progressive MS patients and is further evidence of its neuroprotective effect as retinal thinning is associated with brain volume loss and other measures of MS progression.

However, this is not the only condition that MN-166 is being investigated for, according to news published by the company back in September. MediciNova announced earlier this fall that it had received positive clinical findings for MN-166 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). The results were published in the journal Cancer Chemotherapy and Pharmacology.

Dr. Janette Vardy, Professor of Cancer Medicine, University of Sydney Concord Cancer Centre in Australia, helped lead the research with MediciNova. The authors of the report found that the co-administration of MN-166 with oxaliplatin appeared to result in the improvement or stabilization of oxaliplatin-induced neurotoxicity.

The open-label, sequential crossover study was conducted to determine if MN-166 could reduce acute peripheral neuropathy symptoms in subjects with cancer specifically metastatic upper gastrointestinal or colorectal cancer. A total of 14 patients completed two cycles of oxaliplatin-containing chemotherapy, one cycle with conventional chemotherapy, and one cycle of chemotherapy with concurrent MN-166 treatment.

The subjects underwent a series of assessments for neurotoxicity on Day 3 of each cycle. Once they completed a cycle, they were assessed based on scales including the Oxaliplatin-Specific Neurotoxicity Scale (OSNS), the Total Neuropathy Score Clinical (TNSc), the Functional Assessment of Cancer Therapy/Gynaecologic Oncology GroupNeurotoxicity (FACT/GOG-Ntx13), and the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) neuropathy subscale. Across all neurotoxicity measures, most respondents experienced either an improvement or no worsening of neurotoxicity with MN-166 treatment.

We are very pleased to report positive results from this study, Iwaki said at the time of the results publication. Acute neurotoxicity, which predicts chronic CIPN, usually recurs with oxaliplatin chemotherapy and in most cases, patients experience worsening of neurotoxicity symptoms with continued chemotherapy. What makes this remarkable is that half of participants reported improved symptoms in the acute period and showed improved neurological parameters on clinical assessment with ibudilast treatment.

MN-166 is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor inhibitor. It is also a phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines. MediciNova is developing MN-166 for a wide range of conditions, including progressive MS, ALS and other neurological conditions.

Most read today on BioSpace:

Originally posted here:
MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects - BioSpace

Read More...

Diabetic Neuropathy Drugs Market Growth, Industry Analysis, Size and Share 2026| Pfizer, Novartis, Johnson & Johnson – The Haitian-Caribbean News…

November 30th, 2020 7:53 am

The global Diabetic Neuropathy Drugs market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Diabetic Neuropathy Drugs market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Diabetic Neuropathy Drugs market. The authors of the report profile leading companies of the global Diabetic Neuropathy Drugs market, such as Pfizer, Novartis, Johnson & Johnson, Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceutical, Daiichi Sankyo, Astellas Pharma They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Diabetic Neuropathy Drugs market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Diabetic Neuropathy Drugs market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Diabetic Neuropathy Drugs market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Diabetic Neuropathy Drugs industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Diabetic Neuropathy Drugs market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/2301004/global-diabetic-neuropathy-drugs-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Diabetic Neuropathy Drugs market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Diabetic Neuropathy Drugs market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Diabetic Neuropathy Drugs market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Diabetic Neuropathy Drugs Market by Product: Calcium Channel Alpha-2 Delta Ligand, SNRIs and TCAs, Others

Global Diabetic Neuropathy Drugs Market by Application: , Hospitals, Drug Stores, Others

The report also focuses on the geographical analysis of the global Diabetic Neuropathy Drugs market, where important regions and countries are studied in great detail.

Global Diabetic Neuropathy Drugs Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/2301004/global-diabetic-neuropathy-drugs-market

Key questions answered in the report:

Get Full Report in your Inbox within 24 Hours at USD(3350): https://www.qyresearch.com/settlement/pre/52a1fd0b8152186a4052820d2a5020fd,0,1,global-diabetic-neuropathy-drugs-market

Table Of Contents:

1 Market Overview of Diabetic Neuropathy Drugs1.1 Diabetic Neuropathy Drugs Market Overview1.1.1 Diabetic Neuropathy Drugs Product Scope1.1.2 Market Status and Outlook1.2 Global Diabetic Neuropathy Drugs Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Diabetic Neuropathy Drugs Market Size by Region (2015-2026)1.4 Global Diabetic Neuropathy Drugs Historic Market Size by Region (2015-2020)1.5 Global Diabetic Neuropathy Drugs Market Size Forecast by Region (2021-2026)1.6 Key Regions, Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.1 North America Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.2 Europe Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.4 Latin America Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026) 2 Diabetic Neuropathy Drugs Market Overview by Type2.1 Global Diabetic Neuropathy Drugs Market Size by Type: 2015 VS 2020 VS 20262.2 Global Diabetic Neuropathy Drugs Historic Market Size by Type (2015-2020)2.3 Global Diabetic Neuropathy Drugs Forecasted Market Size by Type (2021-2026)2.4 Calcium Channel Alpha-2 Delta Ligand2.5 SNRIs and TCAs2.6 Others 3 Diabetic Neuropathy Drugs Market Overview by Application3.1 Global Diabetic Neuropathy Drugs Market Size by Application: 2015 VS 2020 VS 20263.2 Global Diabetic Neuropathy Drugs Historic Market Size by Application (2015-2020)3.3 Global Diabetic Neuropathy Drugs Forecasted Market Size by Application (2021-2026)3.4 Hospitals3.5 Drug Stores3.6 Others 4 Global Diabetic Neuropathy Drugs Competition Analysis by Players4.1 Global Diabetic Neuropathy Drugs Market Size by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Neuropathy Drugs as of 2019)4.3 Date of Key Manufacturers Enter into Diabetic Neuropathy Drugs Market4.4 Global Top Players Diabetic Neuropathy Drugs Headquarters and Area Served4.5 Key Players Diabetic Neuropathy Drugs Product Solution and Service4.6 Competitive Status4.6.1 Diabetic Neuropathy Drugs Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Pfizer5.1.1 Pfizer Profile5.1.2 Pfizer Main Business5.1.3 Pfizer Diabetic Neuropathy Drugs Products, Services and Solutions5.1.4 Pfizer Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.1.5 Pfizer Recent Developments5.2 Novartis5.2.1 Novartis Profile5.2.2 Novartis Main Business5.2.3 Novartis Diabetic Neuropathy Drugs Products, Services and Solutions5.2.4 Novartis Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.2.5 Novartis Recent Developments5.3 Johnson & Johnson5.5.1 Johnson & Johnson Profile5.3.2 Johnson & Johnson Main Business5.3.3 Johnson & Johnson Diabetic Neuropathy Drugs Products, Services and Solutions5.3.4 Johnson & Johnson Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.3.5 Eli Lilly Recent Developments5.4 Eli Lilly5.4.1 Eli Lilly Profile5.4.2 Eli Lilly Main Business5.4.3 Eli Lilly Diabetic Neuropathy Drugs Products, Services and Solutions5.4.4 Eli Lilly Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.4.5 Eli Lilly Recent Developments5.5 GlaxoSmithKline5.5.1 GlaxoSmithKline Profile5.5.2 GlaxoSmithKline Main Business5.5.3 GlaxoSmithKline Diabetic Neuropathy Drugs Products, Services and Solutions5.5.4 GlaxoSmithKline Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.5.5 GlaxoSmithKline Recent Developments5.6 Boehringer Ingelheim5.6.1 Boehringer Ingelheim Profile5.6.2 Boehringer Ingelheim Main Business5.6.3 Boehringer Ingelheim Diabetic Neuropathy Drugs Products, Services and Solutions5.6.4 Boehringer Ingelheim Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.6.5 Boehringer Ingelheim Recent Developments5.7 Teva Pharmaceutical5.7.1 Teva Pharmaceutical Profile5.7.2 Teva Pharmaceutical Main Business5.7.3 Teva Pharmaceutical Diabetic Neuropathy Drugs Products, Services and Solutions5.7.4 Teva Pharmaceutical Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.7.5 Teva Pharmaceutical Recent Developments5.8 Daiichi Sankyo5.8.1 Daiichi Sankyo Profile5.8.2 Daiichi Sankyo Main Business5.8.3 Daiichi Sankyo Diabetic Neuropathy Drugs Products, Services and Solutions5.8.4 Daiichi Sankyo Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.8.5 Daiichi Sankyo Recent Developments5.9 Astellas Pharma5.9.1 Astellas Pharma Profile5.9.2 Astellas Pharma Main Business5.9.3 Astellas Pharma Diabetic Neuropathy Drugs Products, Services and Solutions5.9.4 Astellas Pharma Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.9.5 Astellas Pharma Recent Developments 6 North America6.1 North America Diabetic Neuropathy Drugs Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Diabetic Neuropathy Drugs Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Diabetic Neuropathy Drugs Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Diabetic Neuropathy Drugs Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Diabetic Neuropathy Drugs Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Diabetic Neuropathy Drugs Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more:
Diabetic Neuropathy Drugs Market Growth, Industry Analysis, Size and Share 2026| Pfizer, Novartis, Johnson & Johnson - The Haitian-Caribbean News...

Read More...

Leber’s Hereditary Optic Neuropathy Drug Market Size, Analysis, Growth, Trends, Outlook And Forecast By 2027 – The Haitian-Caribbean News Network

November 30th, 2020 7:53 am

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Lebers Hereditary Optic Neuropathy Drug Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Lebers Hereditary Optic Neuropathy Drug Market Overview

The Lebers Hereditary Optic Neuropathy Drug Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Lebers Hereditary Optic Neuropathy Drug market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Lebers Hereditary Optic Neuropathy Drug Market: Competitive Landscape

The Lebers Hereditary Optic Neuropathy Drug Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Lebers Hereditary Optic Neuropathy Drug Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Lebers Hereditary Optic Neuropathy Drug Market Segment by Type:

Lebers Hereditary Optic Neuropathy Drug Market Segment by Application:

Lebers Hereditary Optic Neuropathy Drug Market Regional overview:

In the report, experts analyze and forecast the Lebers Hereditary Optic Neuropathy Drug market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Lebers Hereditary Optic Neuropathy Drug Market Report:

Outlook analysis of the Lebers Hereditary Optic Neuropathy Drug market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Lebers Hereditary Optic Neuropathy Drug market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

More here:
Leber's Hereditary Optic Neuropathy Drug Market Size, Analysis, Growth, Trends, Outlook And Forecast By 2027 - The Haitian-Caribbean News Network

Read More...

Locked In: Breaking the Silence review life-affirming story of a devastating illness – The Guardian

November 30th, 2020 7:53 am

A neurological horror story lies at the centre of Xavier Alfords chilling, stoic and finally revitalising documentary, part of the BBC Storyville strand. Guillain-Barr syndrome is a rare condition that can strike without warning, where the immune system attacks the nerves, sometimes leaving the victim completely paralysed. A passenger in your own body or a weird wormhole you dream all the time is how one person interviewed sums it up though he subsequently recovers.

But director Alford has to suffer a second horror: knowing his fate. Alfords illness, known as multifocal motor neuropathy, is related to Guillain-Barr syndrome but is progressive over many years, palsying the outer extremities first we first see him struggling to grasp his camera. Being, as one clinician points out, the sort of person who wants to know, Alford resolves to learn as much as possible about what awaits him. In what is obviously a therapeutic quest, he spends the film meeting other people in different phases of this chronic neuropathy.

At one point he confronts the worst-case scenario: a patient called Rob, who loses even the ability to communicate with his left eyelid, and has his life support switched off. His wife, while being told it is just a medical decision for which she bears no responsibility, is effectively asked to agree that it is what he would have wanted.

Though the case studies are interesting, Alfords film becomes truly illuminating as he probes this ethical territory in his own life. What is the level of responsibility he has the right to expect of his wife, Anna, and children and his own obligations to communicate his inner experience to them? The film makes this possible for him, but his other half virtually refusing to appear on camera questions if this is appropriate. Who can say? Whats certain is that this bleak, patient inquest is relevant far beyond one rare syndrome.

Locked In: Breaking the Silence is on BFI Player and BBC iPlayer from 30 November.

Go here to see the original:
Locked In: Breaking the Silence review life-affirming story of a devastating illness - The Guardian

Read More...

Storm ID and Zebra Medical Vision to Co-Develop Revolutionary New AI Based Osteoporosis Prevention Solution as Part Of UK-Israel Collaboration -…

November 28th, 2020 7:00 am

EDINBURGH, Scotland & KIBBUTZ SHEFAYIM, Israel--(BUSINESS WIRE)--Scottish digital transformation consultancy Storm ID and Israeli AI start-up Zebra Medical Vision have won a UK-Israel research and development competition with a proposal for a revolutionary, machine learning-driven model for early detection and prevention of osteoporosis to improve patient care and reduce healthcare costs. The collaboration will involve close engagement with clinical teams in NHS Greater Glasgow and Clyde and Assuta Medical Centers.

Osteoporosis is a major public health concern that continues to grow in worldwide importance. Fragility fractures, defined as insufficiency fractures not related to high-impact trauma, are the major complication of this underdiagnosed and undertreated condition. Major osteoporotic fractures result in substantial morbidity and mortality, particularly for hip fractures, which is a major concern for an aging population.

Working in partnership, Storm ID and Zebra Medical Vision are developing a preventative care solution to identify people at risk of osteoporosis. Using ML/AI methodologies, the solution will analyze medical imaging data and patient records to help clinical teams identify and treat people with risk of fractures before they happen.

An international, multidisciplinary team of clinicians, data scientists and computer scientists will work together over 2 years, running clinical trials, implementing the solution in both NHS Greater Glasgow and Clyde and Assuta Medical Centers. The project is co-funded in part by the UK and Israel under the EUREKA framework to foster industrial research collaboration between the UK and Israel.

Paul McGinness, Director at Storm ID said: Were aiming to combine the powerful data exchange capabilities of our own Lenus Health Platform with the machine learning models developed by Zebra Medical Vision to transform osteoporosis screening. By predicting ahead of time the potential risk of bone fracture , we can intervene earlier to treat and manage the risk, which is better for the patient and for the health system.

Ohad Arazi, CEO at Zebra Medical Vision said: Were honored to enhance our collaboration with the NHS and Assuta Medical hospital through this incredible initiative, allowing Zebra Meds solutions to even more widely spread in the UK and Israeli healthcare facilities to bring earlier identification and treatment of patients at risk of a break, which in turn will help healthcare payers and providers.

David Lowe, Emergency Consultant, NHS Greater Glasgow and Clyde, and Clinical Lead, West of Scotland Innovation Hub, said: We are pleased to partner on the development of this innovative new solution for osteoporosis patients through the expertise of the West of Scotland Innovation Hub. This is another example of a successful collaboration between industry and the NHS to move forward innovative healthcare. Our clinical teams at NHS Greater Glasgow and Clyde will support the aim of this project to ultimately identify and treat patients with increased risk of bone breakage before it happens.

Dr. Michal Guindy, Head of Imaging and Innovation at Assuta said: "Being able to re-analyze information from patient records and imaging is an important advantage of modern artificial intelligence. As a center of excellence, performing over 200,000 CTs annually, Assuta is excited to play a significant role in early detection of osteoporosis. By analyzing studies that were done for other clinical indications, we can leverage pre-existing data to help prevent fractures and contribute to solving a public health challenge of growing concern."

Read more on Zebra Medical Visions blog.

About Storm ID and Lenus Health

Storm ID is a digital transformation delivery partner for the healthcare sector.

It developed the Lenus Health Platform to support delivery of new digital health solutions that are continuous, preventative and participatory, and which help transform care pathways.

Lenus enables patient generated health data from digital technologies and consumer health tech such as apps, sensors and wearables to be shared with healthcare professionals and machine learning models to provide decision support, enabling targeted interventions to happen in the community. It supports solutions that reduce unnecessary and expensive hospital admissions including face-to-face appointments, improve patient engagement with their own health and wellbeing and reduce duplication and unnecessary processes through user managed access to patient data.

About Zebra Medical Vision

Zebra Medical Vision provides radiologists with the tools needed to make the next leap in patient care. The demand for medical imaging solutions is continuously increasing, outpacing the supply of qualified radiologists and stretching them to produce more output, without compromising patient care. Only by adopting new technology that significantly enhances the capabilities of radiologists, can this crisis be mitigated. Zebra-Med is empowering radiologists with its revolutionary AI1 offering which helps health providers manage the ever increasing workload without compromising quality.

About NHS Greater Glasgow and Clyde

NHS Greater Glasgow and Clyde is one of 14 regional NHS Boards in Scotland, serving a population of 1.14 million and employing around 39,000 staff. It is the largest NHS organisation in Scotland and one of the largest in the UK.

About Assuta Medical Centers

Assuta Medical Centers is Israels largest and leading private medical solution network comprising seven hospitals and clinics across Israel and providing innovative surgeries and diagnostic procedures in all fields of medicine. Assutas Imaging Institute is the most advanced of its type in Israel and has a team of leading radiologists and nuclear medicine specialists. The Institute offers patients the latest innovations in imaging technology, including advanced CT and PET-CT, MRI, PET-MR, and two-head nuclear imaging camera test results are integrated with other clinical data to enhance the accuracy of the findings. The Institute treats more than 600,000 patients annually.

About EUREKA

EUREKA is an intergovernmental network launched in 1985. Its aim is to support market-oriented R&D and innovation projects by industry, research centres and universities across all technological sectors. EUREKA has 41 full members, including the European Union (represented by the European Commission), 1 partner country (South Korea) and 4 associated members (Argentina, Canada, Chile, South Africa). All 27 EU Member States are also members of EUREKA.

The UK-Israel call for proposals was a joint initiative of Innovate UK and the Israel Innovation Authority based upon the 2017 memorandum of understanding on industrial collaboration between the 2 countries.

Continue reading here:
Storm ID and Zebra Medical Vision to Co-Develop Revolutionary New AI Based Osteoporosis Prevention Solution as Part Of UK-Israel Collaboration -...

Read More...

Hospitals work hard to stay ahead of spike in COVID-19 cases across Western New York – WGRZ.com

November 28th, 2020 7:00 am

Medical experts say preparation and additional materials are making it much easier for front line workers to manage the surge in daily hospitalizations.

NIAGARA COUNTY, N.Y. As the Western New York community continues to follow this trend of rapidly increasing COVID-19 cases and daily hospitalizations, concerns and worry over hospital capacity and lack of resources also continue to rise.

Despite the increasing rise in hospitalizations, local medical experts say the method of care during this surge is significantly different than last spring thanks to the abundance of knowledge, new drug treatments, necessary materials and, perhaps most importantly, a solidified and legitimate plan.

At the start of the pandemic everyone, from lawmakers and healthcare workers, to everyday citizens, was taken by surprise. There was no blueprint on how to a navigate and treat something like this virus, despite other historic pandemics, the novel coronavirus is unique in nature.

Joe Ruffolo is the CEO of Niagara Falls Memorial Medical Center and has been with his team on the front lines since early spring. Ruffolo says, things inside the medical center may look busier as of late, but things feel different.

We have more tools in the tool kit this time around, Ruffolo says.

Another differentiating factor this time around new trends.

We're seeing a lot of younger people being tested positive, where in March and April, there was a significant portion of elderly people that were impacted with the COVID virus, Ruffalo points out.

Ruffolo tells 2 On Your Side, while more patients are coming in, less of them need ventilators. Which frees up a significant amount of space for those high-risk patients in need of intensive care.

Right now, he says, the medical center is seeing (on average) four to eight COVID patients a day. More of them appear relatively healthy, between the ages of 25 and 50, and are responding well to drug therapies that enable them to transfer out of the hospital quicker than before.

Weve developed an outpatient setting where we can bring them in, in a safe environment, provide drug therapy, that would enable them to recover sooner, Ruffolo says.

Another benefit, Ruffolo says, is the abundance of materials. Unlike the first wave, Ruffolos team has more PPE, face masks, gowns, protective face wear and back up beds so theres no worry that hospital doors will be forced to close.

We have over fifty additional beds that we could put in place in various areas for designated COVID clusters or pods, he says.

Though Niagara Countys numbers are significantly lower in comparison to other parts of Western New York, Ruffolo says his entire team, top to bottom, is doing everything possible to stay ahead of the surge.

The best medicine, is always preventative medicine, he says.

Like many of his peers, Ruffolo encourages the public to continue following CDC guidelines and public safety measures. Because, while at the moment hospital systems are managing, its possible for the past to become the present, especially when dealing with fluid medical emergencies like this one.

View post:
Hospitals work hard to stay ahead of spike in COVID-19 cases across Western New York - WGRZ.com

Read More...

Deep Longevity Adds Partnership with My Care Express in Merrillville To Add Biomarkers of Aging and Longevity – WFMZ Allentown

November 28th, 2020 7:00 am

HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; SEHK:0575.HK)'s Deep Longevity, Inc, a company subject to a conditional acquisition by the Group which is a pioneer in deep biomarkers of aging and longevity today announced a collaboration with My Care Express Merrillville to deploy an extensive range of AI-powered aging clocks. Deep Longevity is to develop and provide the customized predictors of human biological age to the network of My Care Express clinicians and to provide a training program in longevity medicine.

Deep Longevityaging clocks are supported by a number of academic publications summarized in a recent review titled "BioHorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities"

My Care Express Merrillville has been a provider of preventative and total health care to its patients since it opened. My Care Express has a unique approach to wellness and longevity by helping patients establish wellness goals to live happier, healthier and longer lives. Deep Longevity and My Care Express will partner to see the impact that the utilization of aging clocks has on their patients. "We have always believed that the more information our patients have regarding their health, the better choices they will make. We believe that implementing aging clocks will give our patients a better understanding of their current health and help them achieve their wellness goals", said Dr. Faiz Shareef.

In the scope of the partnership My Care Express physicians will be trained in deep aging clocks and will be able to provide their customers with AgeMetric reports and engage in advanced research to assess the performance of aging clocks in the context of their wellness journey.

"The traditional approach to preventative medicine is focused on preventing disease by diagnosing the symptoms early or reducing the risks of disease. The AI-guided longevity medicine goes much further than that and is focusing on tracking the person's rates of aging at many levels, identification of longevity bottlenecks, and utilizing the latest advances in science and technology to slow down or reverse biological and psychological aging. We are very happy to have My Care Express join the rapidly growing network of our research and clinical partners focused on providing customers with extra years of productive and happy life", said Alex Zhavoronkov, Chief Longevity Officer of Deep Longevity Inc.

About Deep Longevity

Deep Longevity is subject to a conditional acquisition by Regent Pacific Group Limited (SEHK:0575.HK), a public company whose securities are listed on The Stock Exchange of Hong Kong Limited. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS) solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other experts AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.

http://longevity.ai/

About Regent Pacific (SEHK: 0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness, and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

http://www.regentpac.com/

About My Care Express Merrillville

My Care Express Merrillville is a clinic in Northwest Indiana that provides primary and urgent care with a focus on preventative medicine. My Care Express believes in a proactive approach to healthcare by providing its patients with tools that will help them live longer healthier lives. Located on the border of Indiana and Illinois, My Care Express has a dynamic and diverse practice. For more information visit mycareexpressclinic.com

Here is the original post:
Deep Longevity Adds Partnership with My Care Express in Merrillville To Add Biomarkers of Aging and Longevity - WFMZ Allentown

Read More...

Getting a COVID-19 test ahead of Thanksgiving travel is ‘not as good as staying home: Doctor – Yahoo News

November 28th, 2020 7:00 am

Dr. David Katz, Preventive Medicine Specialist & True Health Initiative President, joined Yahoo Finance Live to discuss the surging number of COVID-19 cases in the U.S. and how the Thanksgiving holiday may impact case numbers.

- We're also breaking records, but not in a good way, when it comes to COVID-19 and the pandemic. Let's invite into the stream, Dr. David Katz, preventative medicine specialist and True Health Initiative president. Good to have you here. We keep hearing the warnings from the Centers for Disease Control-- stay at home, don't travel for Thanksgiving. We see one million people going through TSA checkpoints at airports every day. It seems as if we're building up two weeks from now for something that could really, I'm going to use the word horrific-- something that could be horrific, especially for people who work in the medical profession.

DAVID KATZ: Well, good to be with you, Adam. Happy holiday in spite of it all. And I hope not. You know, in some sense, it's pretty horrific already. We have cases rising all around the country. And in those parts of the country that were not very hard hit already-- and I happen to be in one-- you are, as well, New York City, Connecticut, the Northeast-- we were pretty hard hit over the summer and in the spring. And we're not seeing quite a steeper rise in hospitalization here as many other parts of the country. But much of the country is. So it's pretty bad, already.

I think the question about the holiday is, how careful are people being? Are they getting tested? There's much more testing available than there was before. I think many people are testing before they get together with family. That's not as good as staying home, but it's certainly better than not taking any precautions. I've spoken to my extended social network to find out what are the different plants. I imagine you've done the same, right? Not everybody's doing the same thing.

Some people are staying home. Some are gathering, but in much smaller groups. Many modifications, right? Variations on the theme. So I think if people are suitably careful, then it may be there is no post-holiday surge in the surge that we already have. We're kind of already there. We're not going to know, though, until those couple of weeks roll by. And, you know, there's been so much unpredictability in the pandemic. It's a new pathogen. We're learning by going where we have to go.

Story continues

The best advice, of course, is to be very careful. The most carefully you can be is to stay put. The next most careful would be don't expose yourself to anybody who might transmit the virus to you. Don't expose yourself to anybody who might get the virus from you.

- Dr. Katz, how would you compare what we're seeing now to what we saw last spring? Are the numbers that we're seeing now and the extent of it more alarming?

DAVID KATZ: It's a very similar phenomenon, Seana. It's just more widespread around the country. It was highly concentrated in the Northeast, initially-- in Detroit, in and around Seattle. There are few parts of the country where the virus got a foothold, and it spread. And importantly, it spread across risk tiers. So what we're seeing now is a fairly massive level of transmission, much of it among people who are asymptomatic or minimally symptomatic.

This slight departure, perhaps, from some of my colleagues in public health-- that doesn't bother me all that much. What bothers me is when that group so young healthy people get together with people in higher risk tiers. People with diabetes, people with obesity, heart disease, people over 70, people over 80. Because when they get this virus. They're prone to get very sick. And when we see cases go up without hospitalization going up, that may be circulation among young healthy people-- that's not so dire.

When we see hospitalization go up, ICU populations go up, and death counts go up-- and we're seeing that in much of the country now-- that means we're transmitting the virus to a more vulnerable group. And that's very concerning. So it's not more concentrated than it was in New York, but it's now more widespread around the country. And frankly, similar phenomena in other parts of the world, too. Yeah, Adam, sorry.

- Dr. Katz, we have to wrap up, but really, this is a serious question, because you talked about prevention. Do you have advice here, Doctor? You wear masks all the time, we're all now wearing masks. Those of us who wear glasses, the dreaded fogging up of the glasses-- is there a trick for the mask? Because I know nobody who's been able to solve this.

DAVID KATZ: I wish I had one. It is so annoying, isn't it? Yeah, so listen, I think the best I can say is that you know given the consequences of transmitting this virus to people who are frail or elderly, the minor inconvenience of foggy glasses is something we just need to put up with. But no, actually, we'll have to talk later If either of us finds a solution, we'll share it with the other one. But I'd love to know one, too.

- I actually Scotch taped the top of the-- that worked until you start sweating if you're running or walking. And then--

DAVID KATZ: You know, I'm a skier. You know, we have goggles and anti fog wise. So maybe we should just wear-- we just go all in and wear goggles with our masks. Maybe that would work. I don't know, I haven't tried it.

- Well, you've helped clear the fog here for all of us today. Thank you very much. Dr. David Katz, preventative medicine specialist and True Health Initiative president. Thank you for joining us on Yahoo Finance Live.

Link:
Getting a COVID-19 test ahead of Thanksgiving travel is 'not as good as staying home: Doctor - Yahoo News

Read More...

Real-Life Activities Lead to Happier Teens – Psychiatry Advisor

November 28th, 2020 7:00 am

Teens who participate in in-person after-school activities such as sports, arts, and community programs show higher levels of life satisfaction and optimism, according to a study published in Preventative Medicine. The teens surveyed also reported lower screen time a habit associated with higher levels of anxiety and depression.

Teens tend to engage in both extracurricular activities and screen time. Therefore, the authors wanted to examine time use of both in relation to mental health indicators.

The study included self-reported data from more than 28,000 7th grade students in British Columbia, Canada, who completed a survey in 2014/2015 and 2017/2018.

Of the teens surveyed, 14.47% did not participate in extracurricular activities. For screen time, 48% reported less than 2 hours a day and 47.52% reported 2 hours or more per day.

Extracurricular participation was negatively related to screen time (2 = 573.37, df = 1, P < .001); nonparticipants were more likely to report higher levels of screen time than participants. Among nonparticipants, 66.63% reported longer screen time. Among the teens who participated in extracurricular activities, the number who participated in longer screen time dropped to 46.28%.

Extracurricular participation (est. = 0.23, 99% CI [0.17, 0.28]) and shorter screen time (est. = 0.29, 99% CI [0.20, 0.37]) were associated with higher levels of satisfaction with life. Extracurricular participation (est. = 0.25, 99% CI [0.20, 0.30]) and shorter screen time (est. = 0.31, 99% CI [0.23, 0.40]) were positively associated with optimism.

The teens who did not participate in extracurricular activities and who reported longer screen time also reported higher negative mental health scores.

This study had some limitations. Data were cross-sectional and causality cannot be implied. Mental health measures were not diagnostic or clinical screening measures. And, screen time did not distinguish between forms of screen use, such as smartphone and computer, or type, such as social media.

The researchers also found differences between boys and girls. Longer hours of screen time were consistently more detrimental for the mental health of girls than for boys in this study. In other words, the protective nature of shorter screen time was more important for girls than for boys mental health, the authors concluded.

This finding is consistent with previous research suggesting that long hours of internet use was more common among girls (but not boys) with major depressive symptomatology compared to girls with no or minor depressive symptomatology.

Reference

Oberle E, Ji XR, Kerai S, Guhn M, Schonert-Reichl KA, Gadermann AM. Screen time and extracurricular activities as risk and protective factors for mental health in adolescence: A population-level study. Prev Med. 2020 Oct 16;141:106291. doi: 10.1016/j.ypmed.2020.106291

View post:
Real-Life Activities Lead to Happier Teens - Psychiatry Advisor

Read More...

Health care bills already slated for 2021 session – State of Reform – State of Reform

November 28th, 2020 7:00 am

Shawna De La Rosa | Nov 23, 2020

Several health care bills are slated for consideration when Virginia legislative sessions resume Jan. 13. Some of the highlights are listed below.

Get the latest state-specific policy intelligence for the health care sector delivered to your inbox.

HB188: Health care service estimates

Health care services and payment estimates will be considered in HB188. The bill would require hospitals and practitioners licensed by the Board of Medicine to allow a patient to receive an estimate for a nonemergency procedure or test no later than week after scheduling the procedure. Currently, only hospitals are required to provide those estimates.

HB526 Reproductive health coverage

The HB526 would require health benefit plans to cover the costs of specified health care services, drugs, devices, products and procedures related to reproductive health, including well women preventative visits, counseling for sexually transmitted infections, screenings for certain conditions, folic acid supplements, breastfeeding support, breast cancer chemoprevention counseling, contraception, voluntary sterilization and all other treatments that must be covered under federal law as of Jan. 1, 2019.

HB530 Health plans

The Department of Medical Assistance Services, in collaboration with the State Corporation Commission, will be required to contract with health carriers to offer qualified health plans on the health benefit exchange beginning Jan. 1, 2022, if HB 530 passes.

HB579 Mammogram coverage

House Bill 579 would require health insurers to provide coverage for low-dose screening mammograms after Jan. 1, 2021, if the individual has a family history of breast cancer. If an individual has a family history of breast cancer, insurers would have to cover annual mammograms from age 30 to 49 and biannual mammograms starting at age 50.

HB1036 Preventative mental health screenings

Preventative mental health screenings will be covered for outpatient mental health patients if HB 1036 passes. It would require a health carrier to provide coverage as a preventative service for at least six annual therapy or counseling outpatient screenings or visits with a licensed mental health professional for the early detection or prevention of mental illness. Health carriers would be prohibited from imposing cost-sharing requirements for mandated preventative services.

HB1331 Provider contract provisions

House Bill 1331 would prohibit a health carrier that offers a managed care plan from entering into, extending or renewing a provider contract with a facility unless the provider contract contains certain provisions. Each health provider that provides emergency services at the facility of an in-network provider has agreed to have the reimbursement from the health carrier included as part of the health carriers payment to the facility. It also requires that the health carrier cant be billed separately for emergency or ancillary services provided at the facility. This applies to any laboratory or diagnostic service provided at the facility which is in-network or for the referral to an in-network provider.

See the article here:
Health care bills already slated for 2021 session - State of Reform - State of Reform

Read More...

The New You: How to have a healthier Thanksgiving meal – WKYC.com

November 28th, 2020 7:00 am

Even if you're downsizing your dinner, here are some easy swaps to make the traditional holiday recipes healthier

OHIO, USA All year long I have been counting down to Thanksgiving. The turkey, the dressing and we cant forget about the desserts! Oh, and we cant forget about the real reason for the holiday - getting together with friends and family.

And though some of us are downsizing our dinner tables, or moving to a virtual celebration, most of us are still preparing those traditional recipes.

But this year, I have a new perspective thanks to this "The New You" journey, and Im learning that behind all of that love of family and food can be something thats a danger to your health. So, I went back to my new friend Jim Perko, Executive Chef of Cleveland Clinic's Wellness & Preventative Medicine.

"Studies show everybody will consume between 3-5,000 calories between the food and drinks at holiday thanksgiving meal. Yeah, thats a lot," Jim told me.

But, Jim says it is possible to survive this holiday without gaining weight.

"Some of the pitfalls are, you dont want to starve before the meal because youre just going to overeat. You want to make sure you eat slowly, chew your food well. Give your brain time to catch up with your stomach."

Studies have shown that our overeating can stretch our stomachs leading to weight gain.

And when it comes to the meal, it starts with the turkey. Jim says, stick with the white meat, because there is much more saturated fat in the skin, leg and thigh.

But how you cook the turkey can make a big difference too.

"If you put the dressing between the skin and the breast of the meat, the flesh what happens is the dressing isnt going to overcook. It Is going to protect the jewel that solid muscle of white meat. By the time the white meat is done, it helps it keep it moist," Jim said.

He also suggests that instead of using a gravy or sugar - try adding fruit instead.

"Pears and apples. Try moistening that dressing with the fruit and its adding flavors I dont have to pour a lot of gravy and roux on top of it," Jim explained.

Last week, I tried Jims Mac and Cheese-less recipe, another great option to add to the meal - trust me, it's actually good!

"It is totally plant based. The thickening agent is sweet potatoes and cashews and 100% whole grain pasta. There was no cheese added. No saturated fat," Jim reminded me.

Another staple in my family is ham, but Jim says, it's not the best choice.

"When you have ham its cured with nitrates and salts so its better to just avoid anything cured salty," he explained.

And, if you still have room for dessert at the end of the meal, Jim said, try to just have a taste.

"Maple syrup makes you want more maple syrup. Sweet wants more. So trying to go to make less it will be just enough to let you satisfy your sweet tooth."

Jim was kind enough to share some of his favorite holiday recipes from "The What to Eat When Cookbook."

INGREDIENTS: Four cups water, one cup (5 ounces) raw cashews, 12 ounces 100% whole wheat short elbow pasta, 6 cups (about 28 ounces)sweet potato, peeled, cut into 1/2 to 3/4 inch cubes, 2 teaspoons (or more) mild hot sauce such as Cholula, 1 teaspoon Dijon mustard , 3/4 tablespoon kosher salt, 1/4 teaspoon freshly ground black pepper, 1/4 teaspoon ground nutmeg, 1 pinch cayenne pepper.

VEGAN HOLIDAY DRESSING/STUFFING

MAKES: Fourteen cup serving

INGREDIENTS: 8 cups - 100% Whole Grain Dried Bread, dice, 3 tablespoon Parsley chopped, 2 tablespoon Extra Virgin Olive Oil, teaspoon Salt, 1/8 teaspoon Pepper, 1 teaspoon Poultry Seasoning, 1 teaspoon Sage, 2 cups Vegetable Stock, 1 cup Leeks small dice, 1 cup Onion small dice, cup Celery small dice, cup Carrot small dice, cup Toasted Pecans, cup Toasted Walnuts, 1 cup Unsweetened Pineapple Juice, 1 cup Apples small dice, 1 cup Pears small dice

Wash and small dice the apple placing them in a bowl of pineapple juice to prevent browning. Drain the apples, reserving the liquid. Wash pears and small dice placing and toss them in the reserved pineapple juice to prevent browning, add apples to bowl and set aside. Heat a non-stick skillet and add oil, then add onions season with salt, pepper and cook on medium heat until onions just turn transparent. Add celery, carrots and cook until tender. Add the leeks, cook for 5 minutes, then turn off heat and set pan aside. In a large mixing bowl, combine bread with sauted vegetables, add parsley, poultry seasoning, and sage - mix well.

Add vegetable stock and mix well. Add cut fruit in pineapple juice, nuts and mix well. Use a 2 quart casserole dish that has been wiped with a light film of extra virgin olive oil to prevent sticking; add dressing. Cover with plastic wrap then aluminum foil. Bake for 30 minutes in a pre-heated 400 degree oven.

RUTABAGA, CARROT AND SWEET POTATO MASH

MAKES: 6 Servings Serving Size:cup

INGREDIENTS:1 cups rutabaga - peeled and diced, 1 cups carrot - peeled and diced, 1 cups sweet potatoes - peeled and diced, 32 ounces water, teaspoon salt, teaspoon black pepper

In large saucepan combine rutabaga with vegetable broth and simmer until tender, about 30 minutes. Add carrots and continue simmering until carrots are almost tender, about 5 minutes. Add sweet potatoes and simmer until all vegetables are tender, about another 10 minutes.

Drain the vegetables into a bowl while reserving the liquid. Place liquid back in saucepan, reduce to cup. Turn off heat and add vegetables from bowl back to sauce pan along with salt and pepper. With a potato masher, mash vegetables with reduced liquid until a coarse consistency. If mash needs to be heated more, just heat in saucepan until desired temperature. Remove and serve.

NUTRITIONAL INFORMATION PER SERVING:

For increased flavor, cook vegetables in vegetable broth instead of water.

CULINARY MEDICINE HEALTH TIP:

This recipe shows how to create intensely flavorful cooking liquid by using a vegetable skimmer to remove vegetables after cooking. One can retain and reduce cooking liquid for a 100% natural and extremely flavorful broth that can be added back to the vegetables or used in another application.

PAPAS PUMPKIN PIE-LESS

PREP: 25 minutes, plus overnight soaking

INGREDIENTS:1 cup raw cashews, 4 cups water, 1 sweet potato (14 to 16 ounces), 1 large ripe banana broken into chunks, cup pure unsweetened almond butter, 6 tablespoons raisin reduction, cup unsweetened almond milk, 2 teaspoons vanilla extract, 1 can (15-ounce) pure pumpkin, 5 teaspoons pure maple syrup, 1 teaspoons ground cinnamon, teaspoon ground ginger, teaspoon ground nutmeg

Go here to see the original:
The New You: How to have a healthier Thanksgiving meal - WKYC.com

Read More...

Eighth Symposium on COVID-19: What Have We Learned? How Can We Use What We Have Learned? – Touro College News

November 28th, 2020 6:59 am

An online webinar, the eighth Coronavirus (COVID-19) Symposium is sponsored byNew York Medical College of the Touro College and University System. Continuing Education credits are available upon request.

A presentation by the Center for Disaster Medicine of New York Medical College of the Touro College and University System.

Alan Kadish, M.D.Cardiologist | President, Touro College and University System | President, New York Medical College

Edward C. Halperin, M.D., M.A.Chancellor and CEO, Professor of Radiation Oncology, Pediatrics and History, New York Medical College | Provost for Biomedical Affairs, Touro College and University System

by Robert Amler, M.D., MBADean, School of Health Sciences and Practice, Vice President for Government Affairs, New York Medical College | Former Regional Health Administrator, U.S. Department of Health and Human Services | Former Medical Epidemiologist, Centers for Disease Control and Prevention (CDC)

by Sherlita Amler, M.D., M.S., FAAPCommissioner of Health, Westchester County, NY

by Mill Etienne, M.D., M.P.H., FAAN, FAESAssociate Dean for Student Affairs, Associate Professor of Neurology, School of Medicine House Advisory Dean, New York Medical College

by Kathleen DiCaprio, Ph.D.Assistant Professor of Medical Microbiology and Immunology, Touro College of Osteopathic Medicine

by Tami Hendriksz, DOProfessor and Associate Dean of Academic Affairs, Touro University California College of Osteopathic Medicine

by Marisa A. Montecalvo, M.D. Medical Director, Health Services, Professor of Medicine, New York Medical College | Infectious Disease Specialist

by Neil Schluger, M.D. Barbara and William Rosenthal Chair of the Department of Medicine, School of Medicine, New York Medical College | Director of Medicine, Westchester Medical Center

by Edward C. Halperin, M.D., M.A.Chancellor and CEO, New York Medical College | Provost for Biomedical Affairs, Touro College and University System

Hosted by Alan Kadish, M.D.Cardiologist | President, Touro College and University System | President, New York Medical College

Responses will be provided to the questions submitted in advance of the webinar. Questions may be submitted to covid19updates@touro.edu

Register in advance for this webinar

This meeting has been approved for 1.5 CME credits by the Office of Continuing Medical Education, New York Medical College free of charge as a community service to our Healthcare Providers.

Accreditation Statement: New York Medical College is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

New York Medical College designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support: There is no outside funding for this activity.

Disclosures: All activity faculty and planners participating in continuing medical education activities provided by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with commercial entities whose products are discussed in their presentation and/or with any commercial supporters of the activity.

Read the original:
Eighth Symposium on COVID-19: What Have We Learned? How Can We Use What We Have Learned? - Touro College News

Read More...

Thanks & Giving: Mental Health and the Outdoors Tillamook County Pioneer – Tillamook County Pioneer

November 28th, 2020 6:59 am

EDITORS NOTE: During this season of Thanksgiving, we are reaching out to our writers and readers for inspiration. I dont need to repeat the theme of this years trials and tribulations we plan to provide you with thoughtful, uplifting reading over the next few weeks and throughout the holidays. Lets celebrate thanks and giving. What are you thankful for? Give thanks, and lets all be thankful that we live in this very special corner of the world in a community that cares for EVERYONE. Pioneer contributor Julie Chick shares her love for the outdoors and the science behind the connection to our well-being, and introduces us to another gifted healer in our backyard and the benefits of connecting outside. Share your Thanks & Giving to editor@tillamookcountypioneer.net. Watch for more about La Vida Pacifica and more thanks & giving.

By Sarah Reese and Julie Chick

She says she experienced severe depression at age 13 until she developed a strong love for the mountains through snowboarding a few of years later. Ultimately, without exaggeration, she credits this love of the outdoors for saving her life and setting her on a lifelong course of healing and transformation.As I recently walked a fall dappled trail with Nehalem resident and licensed Acupuncturist and Herbalist, Sarah Reese, LAc, we continued the discussion about the role the outdoors can play on our overall and mental health. Throughout college Sarah cultivated her passion for being in nature through outdoor recreation, and now as an adult says, Being active in the wilderness brings me home within myself and affords me enhanced joy, confidence, peacefulness, and personal empowerment. It has aligned me with my souls purpose and generally made me more comfortable in my own skin. Being in nature allows me to be me to let the soft animal of [my] body love what it loves as Mary Oliver puts it in her poem Wild Geese .

Sarahs educational background is in Classical Chinese Medicine and her interest in the Healing Arts began initially through Transpersonal Counseling Psychology, but ultimately, she received her formal training in East Asian medicine because of her affinity for Holistic medicine and the way it addresses the body, mind and Spirit. The way that she practices medicine is rooted in Daoist philosophy which expresses our intrinsic connection to nature and its cycles, and elucidates the concept that we are as much in the universe as the universe is within us. We are not only affected by nature and its cycles, but we are nature and its cycles. We cannot be separated from our ecology.

Sarah sees the current times we are in as an opportunity to utilize preventative medicine to fortify the immune system, and also to employ natural medicine to combat illness when our bodies are out of balance. For example, simple strategies like getting enough rest, reducing stress, practicing conscious breathing and mindfulness, and moving our bodies in nature all restore balance to our lives and create a state of wellbeing in our bodies that makes it exponentially less likely to become ill. A commitment to self-care now significantly reduces our recovery time if we do become ill. Numerous studies in the US and all over the world have proven the health benefits of being outdoors in green spaces, theres no questions that we can affect and improve our general health profile just by simply being outdoors. Additionally, there is mounting research making the connection between our internal biome (gut bacteria) and mental health.The best way to enjoy the healing powers of nature is to find your own sources of joy and prioritize those. Something as simple as a walk on the beach or around the block, or simply just getting outdoors, can boost your mood, reduce stress and set you on a path of wellness. For the sake of the world and our collective wellness add time outdoors to the list, or if you already know you enjoy time in nature, move that to the top of the list.According to Why green spaces are good for grey matter,* walking between busy urban environments and green spaces triggers changes in levels of excitement, engagement and frustration in the brain, a study of older people has found. Sarah suggests, Now more than ever, its vitally important to reconnect with nature and get ourselves outdoors when we can.Sarahs healing practice is called La Vida Pacifica, which means The Peaceful Life in Spanish, and is also an homage to the beautiful North Pacific Coast that we all love. Through La Vida Pacifica she offers mentorship for people searching for guidance, support, and accountability as they navigate their path of wellbeing. Since there is no one size fits all in Holistic wellness, it has always been her mission to connect with people wherever they are on their healing journey and help them realign with their personal Truth. She serves those answering the call for soul-level work who want to develop their intuition in order to live their lives with more creativity, authenticity and vitality. She does private sessions and consultations (over the phone) with an emphasis on Spirit, Mind, Body integration, and incorporates the outdoors when she can. Sarahs email: lavidapacifica@gmail.com

*University of York. Why green spaces are good for grey matter. ScienceDaily. ScienceDaily, 10 April 2017. Related Post

See original here:
Thanks & Giving: Mental Health and the Outdoors Tillamook County Pioneer - Tillamook County Pioneer

Read More...

Page 328«..1020..327328329330..340350..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick